Relmada Therapeutics, Inc. RLMD Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $8.09M+0.2% | $8.07M+100.0% | $4.04M+43.2% | $2.82M-76.4% | $11.95M+8.6% | ||
| $11.37M-7.2% | $12.26M+94.9% | $6.29M-15.0% | $7.4M+18.1% | $6.27M-22.4% | ||
| $19.46M-4.3% | $20.33M+96.9% | $10.33M+1.0% | $10.22M-43.9% | $18.22M-4.5% | ||
| -$19.46M+4.3% | -$20.33M-96.9% | -$10.33M-1.0% | -$10.22M+43.9% | -$18.22M+4.5% | ||
| $409.8K-11.9% | $465.35K+97.3% | $235.85K-33.5% | $354.86K-46.1% | $658.97K+57.5% | ||
| -$19.05M+4.1% | -$19.87M-96.9% | -$10.09M-2.3% | -$9.87M+43.8% | -$17.56M+5.9% | ||
| -$0.22+24.1% | -$0.29+3.3% | -$0.300.0% | -$0.30+48.3% | -$0.58+6.5% | ||
| -$19.46M+4.3% | -$20.33M-96.9% | -$10.33M-1.0% | -$10.22M+43.9% | -$18.22M+4.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Relmada Therapeutics, Inc. profitable?
- Relmada Therapeutics, Inc. is not currently profitable: it reported a net loss of $58.9M over the trailing twelve months.
- What is Relmada Therapeutics, Inc.'s earnings per share?
- Relmada Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.11.
- Where does Relmada Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.